Stock report · Delisted · Nasdaq
Accelerate Diagnostics Inc (AXDX)
0.04USD Delisted Final close · May 15, 2025
AXDX no longer trades. Accelerate Diagnostics was delisted from the Nasdaq in May 2025.
All prices on this page are historical. The last trade was on May 15, 2025, at $0.04.
AXDX stock price history
Final trading statistics
- Final close
- $0.04
- Final trading day
- May 15, 2025
- Market cap at delisting
- $1.01M
- Shares outstanding
- 25.29M
- Final 52-week range
- $0.01 – $2.09
- Avg. volume (final 3 mo.)
- 1,750,361
- All-time high
- $305.60 · Jun 2014
- All-time low
- $0.03 · May 2025
- Return since IPO
- -99.3%
- Beta
- 0.22
- Book value / share
- −$2.23
- Price / book
- -0.02
About Accelerate Diagnostics Inc
Accelerate Diagnostics was an in vitro diagnostics company focused on serious infections, selling in the U.S. and abroad. Its Accelerate Pheno system identified pathogens and ran antibiotic susceptibility testing (AST) for serious and hospital-acquired infections, covering gram-positive and gram-negative organisms.
The PhenoTest BC Kit, used with that system, helped diagnose bacteremia and fungemia alongside other clinical findings. The Accelerate Arc system automated the cleanup and concentration of microbes from positive blood cultures. The company was also developing the Accelerate WAVE system to run AST directly from positive blood culture bottles and bacterial colonies.
Formerly Accelr8 Technology, it became Accelerate Diagnostics in December 2012. It was incorporated in 1982 and based in Tucson, Arizona. On May 8, 2025, it filed for Chapter 11 in Delaware.
Its stock was delisted from the Nasdaq in May 2025, with the last trade on May 15, 2025 at $0.04.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Tucson, AZ
- Employees
- 107
- IPO date
- November 18, 1996
- Delisted
- May 15, 2025
- SEC CIK
- 727207
Accelerate Diagnostics financials before the delisting
The last 5 fiscal years Accelerate Diagnostics reported as a public company, fiscal year ending December.
AXDX revenue and net income
AXDX earnings per share
AXDX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $11.70M | −$50.0M | −$2.37 |
| FY2023 | $12.06M | −$61.6M | −$2.15 |
| FY2022 | $12.75M | −$62.5M | −$0.76 |
| FY2021 | $11.78M | −$77.7M | −$1.27 |
| FY2020 | $11.16M | −$78.2M | −$1.40 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Accelerate Diagnostics stock FAQ
What happened to Accelerate Diagnostics stock?
Accelerate Diagnostics was delisted from the Nasdaq in May 2025. The final close was $0.04 on May 15, 2025.
Can I still buy AXDX stock?
No. AXDX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on May 15, 2025.
What was the last price of AXDX?
AXDX last closed at $0.04 on May 15, 2025, which valued the company at about $1.01M.
How did Accelerate Diagnostics do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Accelerate Diagnostics reported revenue of $11.70M and net income of −$50.0M.
When did Accelerate Diagnostics go public?
Accelerate Diagnostics shares started trading on November 18, 1996.
AXDX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.